Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabio Angeli

Showing results (31-40 of 313) with videos related to

Pageof 32
Sort By:
European Journal of Internal Medicine|August 18, 2020
Performance of creatinine- and cystatin C-based formulas to estimate glomerular filtration rateGiorgio Gentile, Fabio Angeli, Gianpaolo Reboldi
Cardiology and Therapy|July 12, 2021
Aprocitentan, A Dual Endothelin Receptor Antagonist Under Development for the Treatment of Resistant HypertensionFabio Angeli, Paolo Verdecchia, Gianpaolo Reboldi
Blood Pressure Monitoring|November 29, 2022
Should we rethink the blood pressure targets in hypertension guidelines?Paolo Verdecchia, Fabio Angeli, Giampaolo Reboldi
Journal of Hypertension|August 28, 2024
Antihypertensive drugs in the morning or the evening? A complicated question with no clear answerGianpaolo Reboldi, Fabio Angeli, Paolo Verdecchia
Hypertension Research : Official Journal of the Japanese Society of Hypertension|January 14, 2011
More than a REASON to use arterial stiffness as risk marker and therapeutic target in hypertensionFabio Angeli, Gianpaolo Reboldi, Paolo Verdecchia
Journal of the American Society of Nephrology : JASN|December 20, 2003
Clinical usefulness of ambulatory blood pressure monitoringPaolo Verdecchia, Fabio Angeli, Roberto Gattobigio
Cerebrovascular Diseases (Basel, Switzerland)|February 23, 2013
Multivariable analysis in cerebrovascular research: practical notes for the clinicianGianpaolo Reboldi, Fabio Angeli, Paolo Verdecchia
Circulation|December 6, 2017
The Tale of an Innocent: Intensive Treatment and the J-Curve in the SPRINT Trial (Systolic Blood Pressure Intervention Trial)Paolo Verdecchia, Fabio Angeli, Gianpaolo Reboldi
Journal of the American College of Cardiology|January 28, 2026
The Relation Between Blood Pressure and Outcomes in Diabetes: With or Without the J Curve?Paolo Verdecchia, Fabio Angeli, Gianpaolo Reboldi
European Journal of Internal Medicine|February 15, 2026
Should we really target a higher blood pressure in the presence of left ventricular hypertrophy?Paolo Verdecchia, Fabio Angeli, Gianpaolo Reboldi
Pageof 32

Showing results (31-40 of 313) with videos related to

Sort By:
Pageof 32
European Journal of Internal Medicine|August 18, 2020
Performance of creatinine- and cystatin C-based formulas to estimate glomerular filtration rateGiorgio Gentile, Fabio Angeli, Gianpaolo Reboldi
Cardiology and Therapy|July 12, 2021
Aprocitentan, A Dual Endothelin Receptor Antagonist Under Development for the Treatment of Resistant HypertensionFabio Angeli, Paolo Verdecchia, Gianpaolo Reboldi
Blood Pressure Monitoring|November 29, 2022
Should we rethink the blood pressure targets in hypertension guidelines?Paolo Verdecchia, Fabio Angeli, Giampaolo Reboldi
Journal of Hypertension|August 28, 2024
Antihypertensive drugs in the morning or the evening? A complicated question with no clear answerGianpaolo Reboldi, Fabio Angeli, Paolo Verdecchia
Hypertension Research : Official Journal of the Japanese Society of Hypertension|January 14, 2011
More than a REASON to use arterial stiffness as risk marker and therapeutic target in hypertensionFabio Angeli, Gianpaolo Reboldi, Paolo Verdecchia
Journal of the American Society of Nephrology : JASN|December 20, 2003
Clinical usefulness of ambulatory blood pressure monitoringPaolo Verdecchia, Fabio Angeli, Roberto Gattobigio
Cerebrovascular Diseases (Basel, Switzerland)|February 23, 2013
Multivariable analysis in cerebrovascular research: practical notes for the clinicianGianpaolo Reboldi, Fabio Angeli, Paolo Verdecchia
Circulation|December 6, 2017
The Tale of an Innocent: Intensive Treatment and the J-Curve in the SPRINT Trial (Systolic Blood Pressure Intervention Trial)Paolo Verdecchia, Fabio Angeli, Gianpaolo Reboldi
Journal of the American College of Cardiology|January 28, 2026
The Relation Between Blood Pressure and Outcomes in Diabetes: With or Without the J Curve?Paolo Verdecchia, Fabio Angeli, Gianpaolo Reboldi
European Journal of Internal Medicine|February 15, 2026
Should we really target a higher blood pressure in the presence of left ventricular hypertrophy?Paolo Verdecchia, Fabio Angeli, Gianpaolo Reboldi
Pageof 32